Literature DB >> 32123528

Perspectives of People with Multiple Sclerosis About Helminth Immunotherapy.

Sarah J Donkers, Megan C Kirkland, Marc Charabati, Lisa C Osborne.   

Abstract

BACKGROUND: Due to the chronic and incurable nature of the autoimmune disease multiple sclerosis (MS), some people with MS will seek out alternative therapeutic approaches. Helminth immunotherapy, the deliberate inoculation with helminthic parasites as an intervention to prevent, delay, or minimize progression of autoimmune disorders, is one such approach gaining traction in academic research and with the public. Herein, we explored the perspectives of people with MS regarding helminth immunotherapy and its use in disease management.
METHODS: Interpretive description, a qualitative research approach, was applied to data extracted from online forums. Multiple investigators independently identified, extracted, and analyzed data to develop preliminary codes. Inductive thematic analysis and triangulation were then used to collaboratively establish themes.
RESULTS: Four main themes were generated: experience of living with MS, influential factors in contemplating helminth immunotherapy, logistics of helminth immunotherapy, and concerns about helminth immunotherapy.
CONCLUSIONS: There was a general consensus in publicly available online forums that conventional therapies do not provide meaningful improvement for some people with MS. These people may seek alternative therapies such as helminth immunotherapy. Information on helminth immunotherapy from internet resources (eg, blogs and social media forums) can contain biased and scientifically unsupported opinions. Messages of efficacy and improved quality of life are readily available and may influence people with MS considering helminth immunotherapy as an alternative therapy. Although some people with MS are seeking helminth immunotherapy, clinical trial data do not currently support its use for people with MS.
© 2020 Consortium of Multiple Sclerosis Centers.

Entities:  

Keywords:  Alternative treatment; Helminth immunotherapy; Multiple sclerosis (MS); Online research

Year:  2020        PMID: 32123528      PMCID: PMC7041615          DOI: 10.7224/1537-2073.2019-044

Source DB:  PubMed          Journal:  Int J MS Care        ISSN: 1537-2073


  14 in total

Review 1.  Use of constant comparative analysis in qualitative research.

Authors:  J Hewitt-Taylor
Journal:  Nurs Stand       Date:  2001 Jul 4-10

2.  Complementary/alternative medicine in chronic illness as informed self-care decision making.

Authors:  Sally Thorne; Barbara Paterson; Cynthia Russell; Annette Schultz
Journal:  Int J Nurs Stud       Date:  2002-09       Impact factor: 5.837

3.  Immune monitoring of Trichuris suis egg therapy in multiple sclerosis patients.

Authors:  F Benzel; H Erdur; S Kohler; M Frentsch; A Thiel; L Harms; K-P Wandinger; B Rosche
Journal:  J Helminthol       Date:  2011-08-15       Impact factor: 2.170

Review 4.  Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis.

Authors:  Tomas Olsson; Lisa F Barcellos; Lars Alfredsson
Journal:  Nat Rev Neurol       Date:  2016-12-09       Impact factor: 42.937

5.  Role of return migration in the emergence of multiple sclerosis in the French West Indies.

Authors:  P Cabre; A Signate; S Olindo; H Merle; D Caparros-Lefebvre; O Béra; D Smadja
Journal:  Brain       Date:  2005-09-23       Impact factor: 13.501

Review 6.  Helminthic therapy: improving mucosal barrier function.

Authors:  Martin J Wolff; Mara J Broadhurst; P'ng Loke
Journal:  Trends Parasitol       Date:  2012-03-28

7.  Trichuris suis ova therapy in relapsing multiple sclerosis is safe but without signals of beneficial effect.

Authors:  A Voldsgaard; P Bager; E Garde; P Åkeson; A M Leffers; C G Madsen; C Kapel; A Roepstorff; S M Thamsborg; M Melbye; H Siebner; H B Søndergaard; F Sellebjerg; P Soelberg Sørensen
Journal:  Mult Scler       Date:  2015-02-19       Impact factor: 6.312

Review 8.  Helminth Therapy for MS.

Authors:  Radu Tanasescu; Cris S Constantinescu
Journal:  Curr Top Behav Neurosci       Date:  2015

9.  Therapy satisfaction and adherence in patients with relapsing-remitting multiple sclerosis: the THEPA-MS survey.

Authors:  Rocco Haase; Jennifer S Kullmann; Tjalf Ziemssen
Journal:  Ther Adv Neurol Disord       Date:  2016-03-15       Impact factor: 6.570

Review 10.  Environmental risk factors for multiple sclerosis: a review with a focus on molecular mechanisms.

Authors:  Cullen O'Gorman; Robyn Lucas; Bruce Taylor
Journal:  Int J Mol Sci       Date:  2012-09-18       Impact factor: 6.208

View more
  1 in total

1.  Axenic Caenorhabditis elegans antigen protects against development of type-1 diabetes in NOD mice.

Authors:  Belinda M Jackson-Thompson; Marina Torrero; Blima K Mitre; James Long; Mathanraj Packiam; Edward Mitre
Journal:  J Transl Autoimmun       Date:  2020-08-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.